Updated:
EcoR1 Capital
EcoR1 Capital was established in 2012 by Oleg Nodelman. The firm operates as a registered investment adviser with a mandate centered on biotechnology...
EcoR1 Capital
EcoR1 Capital was established in 2012 by Oleg Nodelman. The firm operates as a registered investment adviser with a mandate centered on biotechnology companies. The strategy centers on long equity holdings in public biotech names alongside selective venture commitments. Confirmed positions include Zymeworks, AnaptysBio, Jazz Pharmaceuticals, Crinetics Pharmaceuticals and uniQure. The firm has also backed private companies such as ReCode Therapeutics, ElevateBio, Eikon Therapeutics, Aktis Oncology and Kumquat Biosciences. Activity spans the United States and Europe. The firm lists three named professionals. It maintains relationships with custodians including J.P. Morgan Securities, Goldman Sachs, BofA Securities and Jefferies. In January 2024 Nodelman spoke at the J.P. Morgan Healthcare Conference on biotech investment strategies. EcoR1 Capital sits alongside the Oleg & Heather Nodelman Joint Revocable Trust as the primary vehicle for the founder’s investment activities. The structure keeps discretionary management inside a single adviser entity rather than a multi-strategy platform.
General information
Firm type
Pension Fund
Year founded
2012
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
357 Tehama Street, Floor 3, San Francisco, CA 94103
Principals
Oleg Nodelman
Founder and Portfolio Manager
Sarah Marriott
Partner, Chief Operating Officer, and General Counsel
Scott Perlen
Chief Financial Officer
Sector focus
Frequently asked questions
Who runs investment decisions at EcoR1 Capital?
Oleg Nodelman serves as founder and portfolio manager. Sarah Marriott acts as partner, chief operating officer and general counsel. Scott Perlen serves as chief financial officer.
Does EcoR1 Capital participate in fund commitments or only direct deals?
The firm holds both public long equity positions and limited partner interests in its own venture vehicles such as EcoR1 Venture Opportunity Funds.
What investment stages does EcoR1 Capital typically target?
Public market holdings range from clinical-stage to commercial biotech companies. Private activity includes early-stage companies through board seats and venture funds.
Where does the underlying wealth come from?
The firm was founded by Oleg Nodelman after his time at BVF Partners. No further wealth-origin details are publicly disclosed.
How is EcoR1 Capital related to BVF Partners?
Oleg Nodelman previously worked as a portfolio manager at BVF Partners before founding EcoR1 Capital in 2012.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on registered investment advisers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: